Insider Selling: Hospira CFO Sells 10,000 Shares of Stock (HSP)
Hospira (NYSE:HSP) CFO Thomas E. Werner sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $55.13, for a total transaction of $551,300.00. Following the sale, the chief financial officer now directly owns 54,614 shares of the company’s stock, valued at approximately $3,010,870. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Hospira in a research note on Thursday, July 31st. They now have a $55.00 price target on the stock, up previously from $42.00. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Hospira in a research note on Thursday, July 31st. They now have a $67.00 price target on the stock. Finally, analysts at Barclays reiterated an “equal weight” rating on shares of Hospira in a research note on Thursday, July 31st. They now have a $47.00 price target on the stock, up previously from $43.00. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $51.38.
Shares of Hospira (NYSE:HSP) traded up 0.84% on Monday, hitting $55.48. 753,099 shares of the company’s stock traded hands. Hospira has a 1-year low of $38.11 and a 1-year high of $56.78. The stock has a 50-day moving average of $52.65 and a 200-day moving average of $47.30. The company has a market cap of $9.361 billion and a P/E ratio of 53.06.
Hospira (NYSE:HSP) last announced its earnings results on Wednesday, July 30th. The company reported $0.72 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.56 by $0.16. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter last year, the company posted $0.55 earnings per share. Hospira’s revenue was up 10.7% compared to the same quarter last year. Analysts expect that Hospira will post $2.43 EPS for the current fiscal year.
Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.